Table 7

Aromatase inhibitors

StudyTrial nameSettingPrimary outcomeMedian follow-upDFS control (%)DFS gainDFS HR*OS controlOS gain (%)OS HR*ESMO-MCBS V.1.1Reference
A 5 years vs Tam 5 yearsATACPostmenopausal HR+DFS120 months76.04.30%0.86 (0.78–0.95)77.5%1.00.95 (0.84–1.06)NEB49–51
L vs Tam (5 years)BIG 1–98Postmenopausal HR+DFS97.2 months72.04.4%0.82 (0.74–0.92)81.4%4.00.79 (0.69–0.90)B53–55
L vs Tam→L vs L→TamBIG 1–98Postmenopausal HR+DFS (Tam→L)71 months87.9−1.71.05 (0.84–1.32)93.4%−1.01.13 (0.83–1.53)B55 59
L vs Tam→L vs L→TamBIG 1–98Postmenopausal HR+DFS (L→Tam)71 months87.9−0.3%0.96 (0.76–1.21)93.4%−0.30.90 (0.65–1.24)B55 59
Tam 2–3→E 2–3 vs Tam 5 yearsIESPostmenopausal HR+ and unknownDFS55.7 monthsAll 3.3%0.76 (0.66–0.88)88.0%1.30.85 (0.71–1.02)B56 57
Tam 2–3→E 2–3 vs Tam 5 yearsIESPostmenopausal HR+DFS55.7 monthsHR+ 3.5%0.75 (0.65–0.87)87.9%1.80.83 (0.69–0.99)A56 57
Tam 2→A 3 years vs Tam 5 yearARNO-95Tam 2→A 3 years vs Tam 5 yearsDFS30.1 months89.34.2%0.66 (0.44–1.00) p=0.04994.3%2.60.53 (0.28–0.99)C58
E vs Tam->ETEAME 5 years vs Tam 2–3 years →E 5 yearsDFS5.1 years85.0**1.0%0.97 (0.88–1.08)91.0%01.00 (0.89–1.14)B52
Tam vs Tam→AITAPostmenopausal HR+ Node+DFS36 months85.88.8%0.35 (0.18–0.68)A48
5 years Tam vs 5 years AI (meta-analysis)EBCTCGPostmenopausal HR+DFS and OS10 years22.73.6%0.80 (0.73–0.88)Breast cancer mortality 14.2%2.10.85 (0.75–0.96)C60
5 years Tam vs 5 years AI (meta-analysis)EBCTCGPostmenopausal HR+DFS and OS10 years22.73.6%0.80 (0.73–0.88)Overall mortality 24%2.70.89 (0.8–0.97)C60
5 years Tam vs Tam→AI (meta-analysis)EBCTCGPostmenopausal HR+DFS and OS10 years19.02.0%0.82 (0.75–0.91)Breast cancer mortality 10%1.50.84 (0.72–0.96)C60
5 years Tam vs Tam→AI (meta-analysis)EBCTCGPostmenopausal HR+DFS and OS10 years19.02.0%0.82 (0.75–0.91)Overall mortality 17.5%2.90.82 (0.73–0.91)C60
Tam→AI vs upfront AI (meta- analysis)EBCTCGPostmenopausal HR+DFS and OS7 years14.50.7%0.9 (0.81–0.99)Breast cancer mortality 9.3%1.10.89 (0.78–1.03)NEB60
Tam→AI vs upfront AI (meta- analysis)EBCTCGPostmenopausal HR+DFS and OS7 years14.50.7%0.9 (0.81–0.99)Overall mortality 14.5%0.90.96 (0.86–1.07)NEB60
  • Chart blanks—relevant variables not available in manuscript.

  • *HR values in parentheses refer to 95% CI.

  • A, anastrozole; AI, aromatase inhibitor; DFS, disease-free survival; E, exemestane; ESMO-MCBS, The European Society for Medical Oncology-Magnitude of Clinical Benefit Scale; HR+, hormone receptor-positive; L, letrozole; NEB, no evaluable benefit; Node+, node-positive; OS, overall survival; Tam, tamoxifen.